Link of apoptosis level in the primary tumor at early stages of non-small cell lung cancer with efficacy of adjuvant polychemotherapy.

O. P. Kolesnik; A. I. Shevchenko; V. O. Tumansky; M. A. Shyshkin; A. V. Yevseyev

doi:10.26641/2307-0404.2013.4.20378

Автор(и)

O. P. Kolesnik
A. I. Shevchenko
V. O. Tumansky
M. A. Shyshkin
A. V. Yevseyev

DOI:

https://doi.org/10.26641/2307-0404.2013.4.20378

Ключові слова:

apoptosis, adjuvant chemotherapy, non-small cell lung cancer, survival

Анотація

One of the important questions in modern oncology is treatment of patients with early stages of non-small cell lung cancer (NSCLC). Adjuvant polychemotherapy (APCT) can help to improve prognosis after operation. In modern literature there is no unified opinion as for patients in need of adjuvant chemotherapy. However, now investigators indicate to necessity to use molecular markers for individualization of APCT. The aim of our study was to assess correlation between apoptos level in primary tumor in patients with early stages of NSCLC with effectiveness of APCT. Study was conducted by the chair of oncology of Zaporozhye state medical university since June 2008 to Dec 2012. 254 patients with I-II stages of non-small cell lung cancer were included in the study. Expression of p53 was evaluated as percent of positively stained nucleus tumor cells in general population. More than 25% of positively stained nucleus tumor cells meant high p53 expression. Results: We performed assessment of apoptosis level with the help of p53 expression in 220 patients. No prognostic significance of p53 level expression in patients with early stages of non-small cell lung cancer (р=0,65) was revealed. There was significant correlation between age (р=0,039), sex (р=0,009) and apoptosis level in primary tumor in patients with early stages of NSCLC. Worse survival was noted in group of patients with low p53 expressions after adjuvant chemotherapy (р=0,009). But in patients with high level of p53 expression adjuvant chemotherapy significantly increased survival (p<0,001). So, adjuvant chemotherapy in patients with I-II stages of NSCLC is necessary to be carried out in cases of high p53 expression level.

Біографії авторів

O. P. Kolesnik

Zaporozhye regional clinical oncology center
chair of oncology ZSMU
Kulturnaya str. 17A, Zaporozhye, 69040, Ukraine

A. I. Shevchenko

Zaporozhye regional clinical oncology center
chair of oncology ZSMU
Kulturnaya str. 17A, Zaporozhye, 69040, Ukraine

V. O. Tumansky

Kulturnaya str. 17A, Zaporozhye, 69040, Ukraine

M. A. Shyshkin

Kulturnaya str. 17A, Zaporozhye, 69040, Ukraine

A. V. Yevseyev

Kulturnaya str. 17A, Zaporozhye, 69040, Ukraine

Посилання

Левченко Е.В. Адъювантная терапия рака лёг¬кого / Е.В.Левченко // Практическая онкология. – 2007. – Т8, №3. – С 135-139.

Суховерша О.А. Патоморфологічні фактори прогнозу як основа оптимізації лікування ІІІА стадії недрібноклітинного раку легень / О.А.Суховерша // Морфологія. – 2007. – Т. 1, № 4. – С. 100-107.

Эллиниди В.Н. Практическая иммуногистоци¬тохимия / В.Н. Эллиниди, Н.В. Аникеева, Н.А. Мак¬симова – СПб. : ВЦЭРМ МЧС России, 2002. – 36 с.

A randomized trial of postoperative adjuvant the¬rapy in patients with completely resected stage II or IIIa non–small-cell lung cancer / S.M. Keller, S. Adak, H. Wag¬ner [et al.] // N. Engl. J. Med. – 2000. – Vol. 343. – P. 1217-22.

Biologic risk model for recurrence in resected early-stage non-small cell lungcancer (ES NSCLC). / K.A. Gold, J.J. Lee, Y. Ping [et al.] // J. Clin. Oncol. – 2011. – Vol. 29, N 15. – P. 7053.

Boenisch T. Immunohistochemical staining met¬hods : handbook / T. Boenisch, A.J. Farmilo, R.H. Stead – 3rd ed. – Carpinteria: Dako Cytomation Corporation, 2001. – 68 p.

Cell Cycle Regulators and Outcome of Adjuvant Cisplatin-Based Chemotherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adju¬vant Lung Cancer Trial Biologic Program / M. Filipits, R. Pirker, A. Dunant [et al.] // J. Clin. Oncol. – 2007. – N 25. – Р. 2735-2740.

Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial / D. Wal¬ler, M.D. Peake, R.J. Stephens [et al.] // Eur. J. Car¬diothorac Surg. – 2004. – Vol. 26. – P. 173-182.

Expression of the p53 Family in Lung Cancer / H. Uramoto, K. Sugio, T. Oyama [et al.] // Anticancer Re¬search. – 2006. – Vol. 26. – P. 1785-1790.

Individualized adjuvant chemotherapy for surgi¬cally resected lung cancer and the roles of biomarkers / N. Ikeda, S. Nagase, T. Ohiro [et al.] // Ann. Thorac Cardio¬vasc. Surg. – 2009. – Vol. 15, N 3. – P. 144-149.

Prognostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer / M.S. Tsao, S. Aviel-Ronen, K. Ding [et al.] // J. Clin. Oncol. – 2007. – Vol. 25. – P. 5240-5247.

Prognostic Evaluation of the Expression of p53 and bcl-2 Oncoproteins in Patients with Surgically Re¬sected Non-small Cell Lung Cancer / R.Sh. Lai, J.S. Wang, H.K. Hsu [et al.] // Japan J. Clin. Oncol. – 2002. – Vol. 32, N 10. – P. 393–397.

Prognostic factors in patients with resected patho¬logic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC) / F. Tanaka, K. Yanagihara, Y. Otake [et al.] // Eur. J. Cardiothorac. Surg. 2001. – Vol. 19. –P. 555-561.

Prognostic Significance of p53 and Ki-67 Antigen Expression in Surgically Treated Non–Small Cell Lung Cancer / C. Maddau, M. Confortini, S. Bisanzi [et al.] // Am. J. Clin. Pathol. – 2006. – Vol. 125. – P. 425-431.

Levchenko EV. Ad’yuvantnaya terapiya raka leg¬kogo. Prakticheskaya onkologiya. 2007;8(3):135-9.

Sukhoversha OA. Patomorfologіchnі faktori pro¬g¬nozu yak osnova optimіzatsії lіkuvannya ІІІA stadії ne¬drіbno¬klіtinnogo raku legen'. Morfologіya. 2007;1(4):100-7.

Ellinidi VN, Anikeeva NV, Maksimova NA. Pra¬k¬ticheskaya immunogistotsitokhimiya. SPb.: VTsERM MChS Rossii, 2002;36.

Keller SM, Adak S, Wagner H. A randomized trial of postoperative adjuvant therapy in patients with com¬pletely resected stage II or IIIa non–small-cell lung cancer. N Engl J Med. 2000;343:1217-22.

Gold KA, Lee JJ, Ping Y. Biologic risk model for recurrence in resected early-stage non-small cell lung¬cancer (ES NSCLC). Journal of Clinical Oncology. 2011;29(15):7053.

Boenisch T, Farmilo AJ, Stead RH. Immuno¬his¬tochemical staining methods: handbook 3rd ed. Carpin¬teria: Dako Cytomation Corporation, 2001;68.

Filipits M, Pirker R, Dunant A. Cell Cycle Re¬gulators and Outcome of Adjuvant Cisplatin-Based Che¬motherapy in Completely Resected Non–Small-Cell Lung Cancer: The International Adjuvant Lung Cancer Trial Biologic Program J. Clin. Oncol. 2007;25:2735-40.

Waller D, Peake MD, Stephens RJ. et al. Chemo¬therapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173-82.

Uramoto H, Sugio K, Oyama T. et al. Expression of the p53 Family in Lung Cancer. Anticancer research. 2006;26:1785-90.

Ikeda N, Nagase S, Ohiro T. Individualized adju¬vant chemotherapy for surgically resected lung cancer and the roles of biomarkers. Ann thorac cardiovasc surg. 2009;15(3):144-9.

Tsao MS, Aviel-Ronen S, Ding K. et al. Pro¬g¬nostic and Predictive Importance of p53 and RAS for Adjuvant Chemotherapy in Non–Small-Cell Lung Cancer. J Clin Oncol. 2007;25:5240-7.

Lai RSh, Wang JS, Hsu HK et al. Prognostic Evaluation of the Expression of p53 and bcl-2 On¬coproteins in Patients with Surgically Resected Non-small Cell Lung Cancer. Jpn J Clin Oncol. 2002;32(10):393–7.

Tanaka F, Yanagihara K, Otake Y. et al. Pro¬gnostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC). Euro¬pean Journal of Cardio-thoracic Surgery. 2001;19:555-61.

Maddau C, Confortini M, Bisanzi S. et al. Prog¬nostic Significance of p53 and Ki-67 Antigen Expression in Surgically Treated Non–Small Cell Lung Cancer. Am J Clin Pathol. 2006;125:425-31.